Philips posts 4% comparable sales growth and margin gain in Q1 2026
Royal Philips delivered a solid opening quarter to 2026, reporting group sales of EUR 3.9 billion — a 4% increase on a comparable basis — alongside a 6% rise in comparable order intake and a 40-basis-point expansion in adjusted EBITA margin to 9.0%. The results came as the Dutch health technology group signalled it is pressing ahead with a new growth plan while navigating tariff headwinds and broader macroeconomic uncertainty.
Chief executive Roy Jakobs said the performance reflected "disciplined execution against our plan in an uncertain macro-environment," with sales growth led by the Personal Health segment, which posted a 9% comparable sales increase and an adjusted EBITA margin of 15.8%. Diagnosis & Treatment grew 2% and Connected Care 3%, though the latter saw its margin contract by 60 basis points to 2.9%, weighed down by tariff costs and higher inflation. Productivity initiatives delivered EUR 126 million in savings in the quarter, keeping Philips on track for its EUR 1.5 billion savings target under the 2026–2028 programme.
AI-powered regulatory wins
The quarter's most substantive technology news was a cluster of FDA 510(k) clearances for AI-enabled imaging systems. SmartHeart automates the planning of 14 standard and advanced cardiac MR views in under 30 seconds — a process the company says reduces breath holds by up to 75%, a meaningful benefit in patient comfort and workflow throughput. DeviceGuide, cleared to integrate with Philips' Azurion image-guided therapy platform, provides real-time AI guidance during complex cardiac procedures including mitral valve interventions.
On the CT side, Verida Spectral CT received clearance to deliver anatomical and functional insights from a single low-dose scan, while Rembra CT combines high speed with an 85 cm wide bore for complex cases. The four clearances, all arriving within a single quarter, are consistent with a broader industry trend toward AI-assisted interpretation and workflow automation across modalities. Philips says it remains the leading MedTech patent applicant at the European Patent Office, a position it is using to support its platform-based commercial strategy.
Market context and competitive positioning
Philips operates in a crowded health-imaging market where rivals including GE HealthCare, Siemens Healthineers, and Canon Medical are pursuing similar AI-integration strategies. What differentiates Philips' current positioning is its emphasis on bundled hardware-software-AI platforms — notably Azurion — and its move toward enterprise service agreements rather than one-off equipment sales. Three long-term service partnerships were announced this quarter with WellSpan Health, University Health San Antonio, and AdventHealth, covering imaging, patient monitoring, and enterprise service delivery across hospital networks. These multi-year deals provide recurring revenue visibility and strengthen switching costs, a dynamic that analysts have increasingly rewarded in medtech valuations.
Tariff exposure remains a material risk; Philips' outlook explicitly excludes any potential refund from the International Emergency Economic Powers Act tariff regime, and the Connected Care margin compression already illustrates the direct cost impact. The company is also separately managing ongoing US Department of Justice proceedings related to the Philips Respironics recall, which is excluded from guidance. For the full year, management reiterated comparable sales growth of 3%–4.5%, adjusted EBITA margin of 12.5%–13.0%, and free cash flow of EUR 1.3–1.5 billion.
With AI clearances stacking up and enterprise partnerships extending its hospital-system footprint, Philips appears to be executing credibly on its repositioning — though the tariff environment and legacy legal obligations continue to represent uncertainties that investors and customers will monitor closely through the remainder of the year.